Home › Myeloproliferative Neoplasms › Arizona › Phoenix
Myeloproliferative Neoplasms clinical trials in Phoenix, AZ
6 studies for Myeloproliferative Neoplasms are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Mayo Clinic Hospital in Arizona, Phoenix
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Mayo Clinic Hospital in Arizona, Phoenix
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- Mayo Clinic Arizona, Phoenix
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Phoenix Childrens Hospital, Phoenix
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Mayo Clinic Hospital, Phoenix
Caris Chromoseq Data Collection
RecruitingObservational study
- Caris Life Sciences, Phoenix
Myeloproliferative Neoplasms trials in other cities
- Houston, TX16 studies
- New York City, NY15 studies
- Boston, MA14 studies
- Miami, FL10 studies
- Milwaukee, WI10 studies
- Durham, NC9 studies
- Baldwin Park, CA9 studies
- Seattle, WA9 studies
- Chicago, IL9 studies
- Cleveland, OH8 studies
- Portland, OR8 studies
- Atlanta, GA8 studies
Other studies in Phoenix
- Breast Cancer25 studies
- Colorectal Cancer25 studies
- Obesity22 studies
- Metastatic Cancer20 studies
- Non-Small Cell Lung Cancer20 studies
- Heart Failure18 studies
- Cancer (all types)17 studies
- Prostate Cancer17 studies
- Cardiovascular Disease16 studies
- Multiple Myeloma16 studies
- Pancreatic Cancer16 studies
- Overweight15 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.